High-flow Nasal Cannula, Non-invasive Positive Pressure Ventilation, Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Conditions
Brief summary
Although non-invasive positive pressure ventilation (NPPV) shows the good curative effect of treating the patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD), some patients do not tolerate NPPV or do not benefit from it. High-flow nasal cannula (HFNC) is well tolerated and may be used to patients with AECOPD who are intolerant to NPPV treatment. This study is to evaluate the physiological effect of HFNC and compare it with NPPV.
Interventions
DEVICEHFNC
HFNC provides warmed and humidified gas administered through slightly enlarged nasal prongs.
DEVICENPPV
NPPV is the standard therapy for ventilatory failure in AECOPD.
Sponsors
The First Affiliated Hospital of Guangzhou Medical University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Caregiver, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* AECOPD patients with acute hypercapnic respiratory failure
Exclusion criteria
* other lung/pleural diseases or thoracic deformity * severe heart failure (New York Heart Association class IV), severe dysrhythmia * unstable angina, or malignant comorbidity * obesity (BMI ≥ 35 kg/m²) * severe obstructive sleep apnea syndrome
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Neural respiratory drive | 30 minutes | Neural respiratory drive is calculated by diaphragm electromyogram |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Work of breathing | 30 minutes | Work of breathing is calculated by the transdiaphragmatic pressure |
| Transcutaneous CO2 | 30 minutes | Transcutaneous CO2 is a non-invasive method estimated the partial pressure of arterial blood CO2. |
Countries
China
Contacts
Primary ContactLili Guan, PhD
Outcome results
None listed